Literature DB >> 11312409

Enhanced inhibition of lymphocyte activation by Mycobacterium avium complex in human T lymphotrophic virus type I carriers.

W Matsuyama1, R Kubota, T Hamasaki, A Mizoguchi, F Iwami, J Wakimoto, M Kawabata, M Osame.   

Abstract

BACKGROUND: We have previously reported that disseminated pulmonary Mycobacterium avium complex (MAC) infection is more common in human T lymphotrophic virus type I (HTLV-I) carriers than in non-carriers. However, the reason for this remains unclear. It has been shown that glycopeptidelipid (GPL), one of the lipid components of the cell envelope of MAC, is able to reduce the lymphocyte blastogenic response to mitogens. The purpose of this study was to clarify whether or not the inhibitory effect of GPL differs between HTLV-I carriers and non-carriers.
METHODS: Peripheral blood lymphocytes were obtained from 29 patients who had recovered from pulmonary MAC infection (10 of whom also had HTLV-I infection) and the lymphocyte counts and T cell subpopulations of the peripheral blood lymphocytes in HTLV-I carriers and non-carriers were compared. The inhibitory effect of GPL on the lymphocyte blastogenic response to phytohaemagglutinin (PHA) was tested in these 29 cases and in 15 healthy controls who had never suffered from MAC (seven of whom also had HTLV-I infection). All HTLV-I positive cases were carriers.
RESULTS: There was no significant difference in the numbers or subset proportions of T cells between HTLV-I carriers and non-carriers. Lymphocyte activation by PHA was significantly inhibited by GPL in MAC positive and negative HTLV-I carriers compared with MAC negative non-carriers and MAC negative healthy controls (p<0.001).
CONCLUSIONS: We suggest that MAC infection leads to strong inhibition of lymphocyte activation in HTLV-I carriers. This may account, in part, for the severity of pulmonary MAC infection in HTLV-I carriers.

Entities:  

Mesh:

Year:  2001        PMID: 11312409      PMCID: PMC1746037          DOI: 10.1136/thorax.56.5.394

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Clinical investigation of pulmonary Mycobacterium avium complex infection in human T lymphotrophic virus type I carriers.

Authors:  W Matsuyama; A Mizoguchi; F Iwami; Y Koreeda; J Wakimoto; H Kanazawa; S Mori; M Kawabata; H Fukunaga; M Osame
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

3.  Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan.

Authors:  N Tachibana; A Okayama; J Ishizaki; T Yokota; E Shishime; K Murai; S Shioiri; K Tsuda; M Essex; N Mueller
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

Review 4.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

5.  Expression of human T lymphotropic virus type 1 (HTLV-1) tax/rex gene in fresh bronchoalveolar lavage cells of HTLV-1-infected individuals.

Authors:  Y Higashiyama; S Katamine; S Kohno; H Mukae; S Hino; T Miyamoto; K Hara
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

6.  Immunological functions and phenotypes of peripheral blood lymphocytes from human T-cell leukemia virus-I carriers.

Authors:  Y Tanaka; S Oda; K Nagata; N Mori; H Sakamoto; S Eto; U Yamashita
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

7.  Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity.

Authors:  I Tsuyuguchi; H Kawasumi; T Takashima; T Tsuyuguchi; S Kishimoto
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group.

Authors:  E L Murphy; S A Glynn; J Fridey; R A Sacher; J W Smith; D J Wright; B Newman; J W Gibble; D I Ameti; C C Nass; G B Schreiber; G J Nemo
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

9.  Thin-layer chromatography of lipid antigens as a means of identifying nontuberculous mycobacteria.

Authors:  P J Brennan; M Heifets; B P Ullom
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

10.  Immunologic assessment of a cluster of asymptomatic HTLV-I-infected individuals in New Orleans.

Authors:  R D deShazo; N Chadha; J E Morgan; V J Shorty; S R Rangan; V S Kalyanaraman; N Hyslop; Y Chapman; S O'Dea
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

View more
  3 in total

1.  Influence of human T lymphotrophic virus type I on diffuse pan-bronchiolitis.

Authors:  M Yamamoto; W Matsuyama; K Oonakahara; M Watanabe; I Higashimoto; M Kawabata; M Osame; K Arimura
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 2.  Health impacts of environmental mycobacteria.

Authors:  Todd P Primm; Christie A Lucero; Joseph O Falkinham
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

3.  Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity.

Authors:  W Matsuyama; M Kawabata; A Mizoguchi; F Iwami; J Wakimoto; M Osame
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.